Patient Profile-Based Management with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Patient Profile-Based Management with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis ; volume:10 ; number:4 ; day:28 ; month:9 ; year:2024 ; pages:377-409 ; date:12.2024
Pulmonary therapy ; 10, Heft 4 (28.9.2024), 377-409, 12.2024
- Creator
-
Viswanathan, Vinod K.
Ghoshal, Aloke G.
Mohan, Anant
Patil, Ketaki
Bhargave, Chaitanya
Choudhari, Sanjay
Mehta, Suyog
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s41030-024-00271-1
- URN
-
urn:nbn:de:101:1-2502042107469.572489048647
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:37 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Viswanathan, Vinod K.
- Ghoshal, Aloke G.
- Mohan, Anant
- Patil, Ketaki
- Bhargave, Chaitanya
- Choudhari, Sanjay
- Mehta, Suyog
- SpringerLink (Online service)
Other Objects (12)
Real-World Experience with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis
Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis
Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Global Pharmacovigilance Data
Pirfenidone vs. nintedanib in patients with idiopathic pulmonary fibrosis: a retrospective cohort study
Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis
Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis
Temporal echocardiographic assessment of pulmonary hypertension in idiopathic pulmonary fibrosis patients treated with nintedanib with or without oxygen therapy
Comparative outcomes in patients receiving pirfenidone or nintedanib for idiopathic pulmonary fibrosis
Patient expectations, experiences and satisfaction with nintedanib and pirfenidone in idiopathic pulmonary fibrosis: a quantitative study
Association between nintedanib adherence trajectory and healthcare use among idiopathic pulmonary fibrosis patients
Cost-Effectiveness Analysis of Nintedanib Versus Pirfenidone in Idiopathic Pulmonary Fibrosis in Belgium
A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK
Real-World Experience with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis
Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis
Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Global Pharmacovigilance Data
Pirfenidone vs. nintedanib in patients with idiopathic pulmonary fibrosis: a retrospective cohort study
Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis
Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis
Temporal echocardiographic assessment of pulmonary hypertension in idiopathic pulmonary fibrosis patients treated with nintedanib with or without oxygen therapy
Comparative outcomes in patients receiving pirfenidone or nintedanib for idiopathic pulmonary fibrosis
Patient expectations, experiences and satisfaction with nintedanib and pirfenidone in idiopathic pulmonary fibrosis: a quantitative study
Association between nintedanib adherence trajectory and healthcare use among idiopathic pulmonary fibrosis patients
Cost-Effectiveness Analysis of Nintedanib Versus Pirfenidone in Idiopathic Pulmonary Fibrosis in Belgium
A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK
Real-World Experience with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis
Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis
Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Global Pharmacovigilance Data
Pirfenidone vs. nintedanib in patients with idiopathic pulmonary fibrosis: a retrospective cohort study
Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis
Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis
Temporal echocardiographic assessment of pulmonary hypertension in idiopathic pulmonary fibrosis patients treated with nintedanib with or without oxygen therapy
Comparative outcomes in patients receiving pirfenidone or nintedanib for idiopathic pulmonary fibrosis
Patient expectations, experiences and satisfaction with nintedanib and pirfenidone in idiopathic pulmonary fibrosis: a quantitative study
Association between nintedanib adherence trajectory and healthcare use among idiopathic pulmonary fibrosis patients
Cost-Effectiveness Analysis of Nintedanib Versus Pirfenidone in Idiopathic Pulmonary Fibrosis in Belgium